Press release
Liver Cirrhosis - Drug Pipeline Landscape, 2023
Read more about this report: https://www.globalinsightservices.com/reports/liver-cirrhosis-drug-pipeline-landscape-2023/
Cirrhosis, also known as liver cirrhosis or hepatic cirrhosis and end-stage liver disease, is a condition characterised by impaired liver function caused by the formation of scar tissue known as fibrosis as a result of liver disease damage.
Cirrhosis is caused by alcoholic liver disease, non-alcoholic steatohepatitis (NASH), her*oin abuse, chronic hepatitis B, and chronic hepatitis C.
Request for a PDF sample copy of report: https://www.globalinsightservices.com/request-sample/GIS31149
Report Highlights
Global Insight Service's, Liver Cirrhosis - Drug Pipeline Landscape, 2023 report provides an overview of the Liver Cirrhosis pipeline drugs. This report covers detailed insights on Liver Cirrhosis drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Liver Cirrhosis pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.
Some of the key players involved in development of Liver Cirrhosis therapeutics are :
• Abalone Bio Inc
• Akaza Bioscience Ltd
• Akero Therapeutics Inc
• AstraZeneca
• BioVie Inc
• Bristol-Myers Squibb Co
• CellionBioMed Inc
• D&D Pharmatech Co Ltd
• Galectin Therapeutics Inc
• Galecto Inc
• GlaxoSmithKline
• Grifols SA
• Hepion Pharmaceuticals Inc
• International Stem Cell Corp
• Inventiva Pharma
• Lipocine Inc
Buy this report: https://www.globalinsightservices.com/checkout/single_user/GIS31149
With Global Insight Services, you receive:
10-year forecast to help you make strategic decisions
In-depth segmentation which can be customized as per your requirements
Free consultation with lead analyst of the report
Excel data pack included with all report purchases
Robust and transparent research methodology
Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: info@globalinsightservices.com
Phone: +1-833-761-1700
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Liver Cirrhosis - Drug Pipeline Landscape, 2023 here
News-ID: 2869634 • Views: …
More Releases from Global Insight Services
Rice Bran Oil Market Is Anticipated To Expand From $7.6 Billion In 2024 To $13.1 …
Market Overview
The Rice Bran Oil Market has emerged as a dynamic segment within the global edible oil industry, owing to its exceptional nutritional benefits and wide applications. Extracted from the outer layer of rice grains, rice bran oil is recognized for its high smoke point, light taste, and health-enhancing properties. Increasing consumer awareness of healthy cooking oils, combined with the growing prevalence of lifestyle-related health concerns such as obesity and…
Continuous Renal Replacement Therapy Market Is Anticipated To Expand From $1.95 …
Market Overview
The Continuous Renal Replacement Therapy (CRRT) Market plays a vital role in modern critical care medicine, particularly for patients suffering from acute kidney injury (AKI). Unlike traditional dialysis methods, CRRT provides continuous and gentle filtration of blood, making it well-suited for unstable patients in intensive care units. The market encompasses dialysis machines, hemofilters, replacement fluids, and related consumables that support hospitals and ICUs in managing critically ill individuals. Growth…
Advanced Air Mobility Market Poised to Grow from $8.7 Billion in 2024 to $45.2 B …
The Advanced Air Mobility (AAM) market is entering an era of rapid transformation, poised to expand from $8.7 billion in 2024 to $45.2 billion by 2034, growing at a CAGR of approximately 17.9%. This remarkable growth reflects the increasing demand for next-generation aerial transportation systems, primarily built around electric vertical takeoff and landing (eVTOL) aircraft and drones. These innovations aim to revolutionize short-distance travel, enhance urban connectivity, and alleviate congestion…
Life Science Tools Market Poised to Grow from $95.7 Billion in 2024 to $170.2 Bi …
The Life Science Tools Market is experiencing remarkable growth, expanding from an estimated $95.7 billion in 2024 to $170.2 billion by 2034, at a CAGR of around 5.9%. This market serves as the backbone of research and development in biotechnology, pharmaceuticals, and healthcare, offering an extensive range of products like advanced instruments, reagents, consumables, and software solutions. These tools enable researchers to conduct experiments, develop diagnostics, and advance therapeutic innovations,…
More Releases for Cirrhosis
Cirrhosis Pipeline: Novel Antifibrotic Therapies and Regenerative Approaches Red …
The treatment landscape for cirrhosis, a progressive liver condition marked by fibrosis and compromised liver function, is witnessing a transformative shift as biopharmaceutical companies advance beyond symptomatic management to target the underlying causes of liver damage. With no approved therapies to reverse established fibrosis, there is a growing focus on antifibrotic agents, hepatoprotective compounds, and regenerative therapies that aim to halt or reverse disease progression. Companies like Ocera Therapeutics, Gilead…
Liver Cirrhosis - Drug Pipeline Landscape, 2023
Cirrhosis, also known as liver cirrhosis or hepatic cirrhosis and end-stage liver disease, is a condition characterised by impaired liver function caused by the formation of scar tissue known as fibrosis as a result of liver disease damage. Cirrhosis is caused by alcoholic liver disease, non-alcoholic steatohepatitis (NASH), chronic hepatitis B, and chronic hepatitis C.
To Remain 'Ahead' Of Your Competitors, Request for A Sample: https://www.globalinsightservices.com/request-sample/GIS31149
Cirrhosis symptoms emerge slowly until liver…
Primary Biliary Cirrhosis - Drug Pipeline Landscape, 2023
New York, Global Insight Services have recently published a report on Primary Biliary Cirrhosis - Drug Pipeline Landscape. The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration.
Read more about Primary Biliary Cirrhosis - Drug Pipeline here: https://www.globalinsightservices.com/reports/primary-biliary-cirrhosis-primary-biliary-cholangitis-drug-pipeline-landscape-2022/
Primary Biliary Cirrhosis (Primary Biliary Cholangitis) is a chronic disease in which the small bile ducts in the liver become injured and inflamed…
Primary Biliary Cirrhosis - Drug Pipeline Landscape, 2022
Global Insight Services have recently published a report on Primary Biliary Cirrhosis - Drug Pipeline Landscape. The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration.
Primary Biliary Cirrhosis (Primary Biliary Cholangitis) is a chronic disease in which the small bile ducts in the liver become injured and inflamed and are destroyed eventually.
Read more about Primary Biliary Cirrhosis - Drug Pipeline…
Global Liver Cirrhosis Market Growth 2018-2023
Market Research Report Store offers a latest published report on Liver Cirrhosis Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Liver Cirrhosis players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.To analyze the Liver Cirrhosis with respect to individual…
Liver Cirrhosis Market Report 2018: Segmentation by Product (Alcoholic Cirrhosis …
Global Liver Cirrhosis market research report provides company profile for Bristol-Myers Squibb, Conatus Pharmaceuticals, Gwo Xi Stem Cell Applied Technology, Instituto Grifols, Intercept Pharmaceuticals, F Hoffman La-Roche, GlaxoSmithKline, Gilead Sciences, Johnson & Johnson, Merck and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate,…
